Neurobiological Technologies, Inc.
NTII
$0.00
$0.000.00%
OTC PK
| 12/17/2009 | 09/30/2009 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -62.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -62.99% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -62.99% | |||
| SG&A Expenses | -24.49% | -21.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.49% | -11.76% | |||
| Operating Income | -112.88% | -66.32% | |||
| Income Before Tax | -109.18% | -61.13% | |||
| Income Tax Expenses | -144.79% | -- | |||
| Earnings from Continuing Operations | -108.55% | -61.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -108.55% | -61.81% | |||
| EBIT | -112.88% | -66.32% | |||
| EBITDA | -112.77% | -66.27% | |||
| EPS Basic | -108.52% | -62.13% | |||
| Normalized Basic EPS | -111.27% | -64.36% | |||
| EPS Diluted | -110.00% | -62.26% | |||
| Normalized Diluted EPS | -111.28% | -64.39% | |||
| Average Basic Shares Outstanding | 0.20% | 0.84% | |||
| Average Diluted Shares Outstanding | 0.14% | 0.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||